ApoB

Apolipoprotein B (apoB) is a structural protein that wraps every atherogenic lipoprotein particle in your blood. LDL, VLDL, IDL, and Lp(a) each carry exactly one molecule. Because of that one-to-one relationship, your apoB number is a direct count of atherogenic particles circulating in your bloodstream. Particle count, not cholesterol weight, drives plaque buildup.

Why particle count beats LDL-C

Standard lipid panels report LDL cholesterol (LDL-C), a measure of the weight of cholesterol carried inside LDL particles. That's a proxy, and sometimes a poor one. A 2022 analysis found that apoB is the best single predictor of cardiovascular risk, superior to LDL-C, non-HDL cholesterol, and particle size [1]. The size distinction matters: cardiologist Ronald Krauss's work linked small, dense LDL particles to cardiovascular risk [2], and that observation still stands. Krauss identified a marker of metabolic dysfunction; what you measure and treat is the count of particles, not their dimensions.

LDL-C and apoB can diverge. Someone with normal LDL-C can carry a high particle burden. Improved apoB with unremarkable LDL-C is an under-recognized pattern that a standard lipid panel misses entirely [3]. This discordance is the practical reason apoB (or non-HDL-C as a reasonable substitute) belongs in routine screening.

Causality and cumulative exposure

The causal link between apoB-carrying lipoproteins and atherosclerotic cardiovascular disease (ASCVD) is among the most robustly established relationships in preventive medicine. Mendelian randomization studies use people with genetic variants that keep LDL lifelong-low as natural experiments. Combined with decades of trial data, they converge on the same conclusion: atherogenic particles cause ASCVD, and lower lifetime exposure means lower lifetime risk [4].

The cumulative-exposure framing changes how you think about timing. Risk accumulates like compound interest. Decades of modestly improved apoB build plaque long before a 10-year risk calculator flags a problem. Standard risk scores are built around middle-aged populations and structurally under-flag younger people with persistently high apoB [3, 4].

Statin trials quantify the treatment benefit clearly: each 1 mmol/L reduction in LDL translates to roughly a 22% relative reduction in major cardiovascular events, dose-dependently, across many baseline risk levels [5]. The concern that statins cause widespread muscle damage is not well supported in blinded trials. The myalgia many people attribute to statins is largely a nocebo effect. A small but real signal for new-onset diabetes exists; current evidence shows the cardiovascular benefit outweighs it [5].

HDL: a marker you cannot treat

"Good cholesterol" language has shaped decades of clinical thinking and deserves correction. Raising HDL-C does not reduce cardiovascular events. Trials of CETP inhibitors (designed specifically to raise HDL-C) failed to show benefit, niacin trials showed net harm [6, 7], and Mendelian randomization in people with genetically high HDL shows no cardiovascular protection. Verhoeven's analysis of the trial and genetic data suggests HDL-C functions as a neutral risk marker rather than a causal protective factor [8]. Low or high HDL can flag other problems and may merit further investigation, but HDL is not a treatment target. ApoB is.

A secondary pathway to watch: TMAO

Gut bacteria convert carnitine and choline, abundant in red meat and eggs, into trimethylamine N-oxide (TMAO). Wang and Hazen's research found that TMAO correlates with atherosclerosis in humans and promotes it in mouse models [9], suggesting a microbiome-mediated route from diet to cardiovascular risk that operates independently of apoB.

Treat this as a live research lead rather than an established target. TMAO also rises after eating fish and in people with kidney disease, and Mendelian randomization data supporting a causal role remain weak. The apoB pathway has decades of converging evidence; the TMAO pathway does not yet.

Where the evidence is unsettled

The causal model linking high apoB to ASCVD is solid across most populations. One group complicates the picture: so-called Lean Mass Hyper-Responders, people who adopt ketogenic diets and develop high LDL-C alongside low triglycerides, high HDL, and otherwise favorable metabolic markers. Whether the standard risk model applies to this phenotype is an open question the existing trial data cannot definitively answer. Relevant prospective data are still accumulating. This is not a settled debate on either side, and LampHill will cover it separately.

Lp(a) is a separate apoB-carrying particle with its own genetic risk axis, partially independent of LDL. People with high Lp(a) carry improved risk even when standard apoB-lowering therapy has been fully optimized. That distinction matters clinically and receives full treatment in the Lp(a) article.

References

1. Marston et al. 2022, JAMA Cardiol — apoB primary risk driver · PubMed 34773460
2. FoundMyFitness — Ronald Krauss: LDL particle size & atherogenic dyslipidemia
3. Attia #229 — understanding CVD risk, cholesterol & apoB (Dayspring-based)
4. Ference et al. 2017, Eur Heart J — LDL causes ASCVD (EAS consensus) · PubMed 28444290
5. CTT/Baigent 2010, Lancet — statin LDL-lowering meta-analysis · PubMed 21067804
6. raw/physionic/nad-nmn/08-niacin-b3-reduce-heart-disease-study198-201.txt
7. AIM-HIGH 2011, NEJM (Boden) — niacin futility · PubMed 22085343
8. Physionic (Verhoeven) — doctors were wrong about (HDL) cholesterol
9. Wang & Hazen 2011, Nature — gut TMAO & cardiovascular disease · PubMed 21475195